Dolutegravir-Based ART Viral Load Suppression Cohort in Lesotho, 2020-2023

Maseru, Lesotho, is the geographic scope for this retrospective cohort study of 397 adults living with HIV who initiated Dolutegravir-based antiretroviral therapy between January 2020 and December 2023. The dataset, authored by Tokelo Molise, shows viral suppression rates of 96% at six months and 97% at twelve months. It was used to examine treatment outcomes and associated factors using descriptive statistics and logistic regression.

Use Cases

• Modeling factors associated with viral suppression based on patient age and gender mentioned in the description
• Evaluating the real-world effectiveness of Dolutegravir-based ART regimens over a 4-year period
• Analyzing temporal trends in treatment outcomes at six- and twelve-month intervals
• Benchmarking clinical performance for age-responsive HIV program planning

Strengths

• Contains records for 397 patients with a defined temporal coverage from 2020 to 2023
• Reports specific, high viral suppression rates of 96% at six months and 97% at twelve months
• Focuses on a specific geographic region (Maseru, Lesotho) and treatment regimen (DTG-based ART)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect geographic and temporal bias inherent to a single-site, retrospective study

Provenance

Source

figshare

Collection Method

Retrospective cohort analysis of patient records

Time Range

January 2020 to December 2023

Freshness

Last updated 2026-04-22 12:44:13; freshness should be verified

Geography

Maseru, Lesotho